NEWARK, Delaware, and NANJING, China. September 13, 2021 – Biosion Inc., announced the appointment of Dr. Yao-Yao Zhu as Head of Global Regulatory Affairs. Dr. Zhu joins Biosion from U.S. FDA where she served as Medical Officer in the Office of Immunology and Inflammation, Office of New Drugs, Center for Drug Evaluation and Research (CDER).

“We are pleased to welcome Yao-Yao to the executive team of Biosion. “Yao-Yao’s exceptional knowledge and experience, both as a physician and as a medical reviewer of novel gene and cell therapy programs at US FDA, will enable Biosion to accelerate regulatory filings and clinical development of our innovative biotherapeutics portfolio in immune and oncology-related diseases” said Dr. Hugh Davis, Chief Operating Officer and President of Biosion USA, Inc.  “In Dr. Zhu’s role as Head of Global Regulatory Affairs she will build Regulatory teams in both the U.S. and China, enabling Biosion to execute clinical development programs worldwide. In addition, Yao-Yao will be integral to developing and driving portfolio and corporate strategy for the next stage of our growth.”

Dr. Zhu brings to Biosion substantial regulatory experience as a medical officer/clinical reviewer at US FDA.  In this capacity Dr. Zhu participated in the review of both biologics and small molecule products with a wide range of indications at different stages of clinical development, contributing as a primary reviewer to the market approval of BYLVAY™, TRALEMENT®, LUXTURNA®, DUCORD, and LAVIV™. In addition, Dr. Zhu has over 20 years of clinical experience as an internal medicine physician, practicing and teaching at medical centers such as the Greater Baltimore Medical Center and Johns Hopkins School of Medicine. Dr. Zhu obtained her M.D. from Peking University Health Science Center. She also holds a Ph.D. degree in Neuroscience from Baylor College of Medicine and post-doctoral training in gene therapy of bone diseases from the University of Michigan.

About Biosion, Inc.

Biosion is a leading “In Global For Global” biotech company with corporate vision of delivering breakthrough therapeutics to patients worldwide. The company is building up its innovative clinical pipeline through internal R&D programs, co-development programs with partners and in-licensing efforts.

The Company integrates several internally-derived proprietary technologies including its H3 hybridoma platform, SynAbTM synergistic antibody technology, SynTracerTM internalization platform, and FlexibodyTM bispecific platform to significantly accelerate its discovery efforts for novel molecules. The company has operations in Newark, Delaware and Nanjing, China. For more information and full pipeline details, please visit www.biosion.com.

Contacts:

Ailie Su, Biosion, Inc. Nanjing, China +86-199-5241-5530, ailie.su@biosion.com 

Shengmei Ma, Biosion USA, Inc.  Newark, DE +1-508-410 6008,  shengmei.ma@biosion.com